.jpg)
GT Biopharma, Inc. issued the following announcement on Mar. 3.
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO, will participate in a fireside chat in-person at the 34th Annual ROTH Conference on Tuesday March 15, 2022, at 8:30 AM PT. Dr. Berk, will be available for one-on-one meetings throughout the event.
The ROTH Conference will consist of 1-on-1 and small group meetings, analyst-selected fireside chats, thematic industry panels, and on-demand presentations by executive management from approximately 400 private and public companies in a variety of growth sectors.
To arrange a one-on-one with GT Biopharma please email oneononerequests@roth.com or contact your ROTH sales representative to arrange.
To submit a registration request or learn more please visit: https://ibn.fm/ROTH2022Registration.
Original source can be found here.
Alerts Sign-up